QUANTA-SYSTEM
31.1.2024 07:31:25 CET | Business Wire | Press release
Quanta System proudly opens the door to the New Year by unleashing the ultimate innovation in the picosecond laser technologies: Discovery PICO with VarioPulse Technology®. An unprecedented level of precision and versatility in a device that allows you to select the picosecond pulse-duration to personalize the treatments to meet the unique needs of each person.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130556983/en/
Pico Filling Treatment - skin rejuvenation (Photo: Business Wire)
Quanta System has always been committed to follow the evolving needs of the market and to listen and understand the needs of its customers. Discovery PICO VarioPulse Technology® represents a significant leap forward in the world of aesthetic medicine.
Featuring Pico Boost technology that can deliver up to 1.8GW of laser power perfectly controlled by the VarioPulse Technology®, this next-generation device welcomes you to 3 cutting-edge customized treatments that are precisely designed to perform tattoo removal and skin revitalization at their best.
Pico Tune-Ink, the adaptable treatment that removes tattoo ink of a wide variety of colour and complexity;
Pico Filling, the no down-time treatment that revitalizes the skin from within and improve its appearance;
Pico Plasma, the all round skin remodeling treatment that targets scars and acne scars.
Commenting on this major launch, Girolamo Lionetti, CEO of Quanta System, expresses his excitement, "We are thrilled to bring this new technology to the aesthetic world. Our primary goal of improving people's quality of life is greatly enhanced by continuing to work alongside our valued partners, the physicians, and providing patients with more and more customized treatments.”
This is just the first step of a new era laser roadmap focused on delivering the superior user experience and patient satisfaction that the market has been waiting for.
For more information about Discovery PICO VarioPulse Technology®, visit our website www.quantasystem.com or come to discover it in person at IMCAS Booth U322 Level 3 - February 1st -3rd 2024.
About Quanta System
For almost forty years Quanta System, a 100% Italian company distributed worldwide, is the reference point for the research, designing and manufacture of state-of-the-art laser systems for surgery, dermatology and aesthetic medicine and the conservation of art works.
In 2004 the company joins El.En. SpA, leader on the laser market listed on the Euronext STAR Milan ("STAR") of the Italian Stock Exchange and a partner of reference for health facilities, Institutions and Entities engaged in scientific and research projects at a global level.
Designed to be used by doctors, specialised operators and restorers, today the Quanta System lasers represent the "Gold Standard" thanks to a wide range of applications.
The laser systems are entirely manufactured in Italy: from Research & Development to production, the entire process takes place in the company's headquarters in Samarate (in the province of Varese).
Quanta System is a trusted partner, day in day out, of all doctors in every part of the world thanks to its ability to listen, its straightforward debates and the creation of new systems that increasingly meet the real needs of professionals so they can provide better care for their patients.
A constantly evolving company that has managed to update its production so that it has always managed to satisfy the developing needs of its time, without losing sight of its primary objective: contributing to the improvement of people's quality of life.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130556983/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom